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The human ribosomal protein L7a is a component of the major
ribosomal subunit. We previously identified three nuclear-localiz-
ation-competent domains within L7a, and demonstrated that the
domain defined by aa (amino acids) 52–100 is necessary, although
not sufficient, to target the L7a protein to the nucleoli. We now
demonstrate that L7a interacts in vitro with a presumably G-rich
RNA structure, which has yet to be defined. We also demonstrate
that the L7a protein contains two RNA-binding domains: one
encompassing aa 52–100 (RNAB1) and the other encompassing
aa 101–161 (RNAB2). RNAB1 does not contain any known
nucleic-acid-binding motif, and may thus represent a new class
of such motifs. On the other hand, a specific region of RNAB2
is highly conserved in several other protein components of the
ribonucleoprotein complex. We have investigated the topology of
the L7a–RNA complex using a recombinant form of the protein
domain that encompasses residues 101–161 and a 30mer poly(G)
oligonucleotide. Limited proteolysis and cross-linking experi-
ments, and mass spectral analyses of the recombinant protein
domain and its complex with poly(G) revealed the RNA-binding
region.
Key words: RNA-binding motif, small nuclear RNA (snRNA),
ribosomal protein, ribosome biogenesis, limited proteolysis
analysis.
INTRODUCTION
The assembly of ribosomes takes place in the nucleolus and
requires a number of co-ordinated events prior to nuclear export
of the mature subunit to the cytoplasm [1]. These events include
nucleolar transcription and processing of 18 S, 28 S and 5.8 S
rRNA, nuclear import and nucleolar accumulation of ribosomal
proteins (r-proteins), as well as nuclear transcription and nucleolar
accumulation of 5 S rRNA. Thus the biogenesis of eukaryotic
ribosomes requires complex intracellular trafficking to ensure
that all the components necessary for efficient ribosome subunit
assembly are present in the nucleoli. Import signals have been
mapped in a number of r-proteins [2,3]; a common feature is their
very basic nature and a greater complexity as compared with the
classical nuclear localization sequence [4]. r-proteins enter the nu-
cleus via a non-classical pathway [5]; once in the nucleus, they are
sequestered in the nucleolus by different pathways, depending on
a specific binding host in the nucleolus, as occurs for some non-
ribosomal nucleolar proteins [6,7].
We previously showed that nucleolar accumulation of L7a
in the nucleoli requires the presence of an essential domain
that spans aa (amino acids) 52–100, and a positively charged
stretch of amino acids that includes a nuclear localization
sequence [3]. These results support the hypothesis that nucleolar
targeting is mediated by interactions between one or more
protein domains and macromolecules residing in the nucleolus
[8,9].
The ribosome is an ancient protein–RNA complex, and r-pro-
teins may have been among the first proteins to set up strategies to
contact RNA. A putative RNA-binding motif (residues 129–160)
has been identified in L7a on the basis of a predicted secondary
structure similarity with an RNA-binding domain identified
in some r-proteins and non-r-proteins [10]. Consequently, L7a
belongs to a family of proteins (L7ae) that share a conserved
region which is larger than the previously predicted RNA-binding
domain, and that spans aa 135–189 in human L7a. This family in-
cludes Haloarcula marismortui L7ae, human r-protein S12, yeast
r-protein L30, yeast protein NHP2 and the human orthologue
15.5 kDa tri-snRNP (small nuclear ribonucleoprotein) [11,12].
Most of these proteins are components of the RNP (ribonu-
cleoprotein) complex. Furthermore, H. marismortui L7ae, yeast
r-protein L30 and human 15.5 kDa tri-snRNP are known to bind
a conserved RNA structural motif [13–15]. As a step toward a
more detailed understanding of the mechanism of nucleolar
accumulation of L7a, we have investigated the RNA-binding
ability of L7a. Our results show that, in addition to the predicted
RNA-binding domain (RNAB2), the domain previously shown to
be essential for nucleolar accumulation of the human L7a r-protein
[3] also exerts RNA-binding activity (RNAB1).
In the present study we report results leading to the definition
of the L7a RNA-binding domains and the analysis of their
specificities. A recombinant form of RNAB2, i.e. L7a(101–161),
was expressed in Escherichia coli, purified and fully chara-
cterized. Topological investigation of this mutant protein and its
complex with poly(G), carried out by limited proteolysis and
cross-linking analysis, led to the definition of the RNA-binding
region and provided experimental evidence of conformational
changes induced by RNA–protein interactions.
Abbreviations used: aa, amino acids; EMSA, electrophoretic mobility-shift assay; ESMS, electrospray MS; GST, glutathione S-transferase; IPTG,
isopropyl β-D-thiogalactoside; LCMS, liquid chromatography MS; MALDI, matrix-assisted laser-desorption ionization; MALDI–TOF, MALDI–time-of-flight;
RNP, ribonucleoprotein; r-protein, ribosomal protein; SECIS, selenocysteine insertion sequence; SBP2, SECIS-binding protein 2; snoRNA, small nucleolar
RNA; snRNA, small nuclear RNA; snRNP, small nuclear RNP; TFA, trifluoroacetic acid.
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EXPERIMENTAL
Plasmid constructs
To express recombinant r-protein L7a and L7a deletion mutants,
we used the pRSET (Invitrogen) and pQE (Qiagen) vectors, both
of which direct the production of histidine-tagged recombinant
proteins. The pQE31/L7a construct encoding an L7a–His cDNA
was generated by inserting an EcoR1–Pst1 fragment of L7a/
pBTM116, containing the entire L7a coding region, into the SmaI–
Pst1 sites of pQE31 after filling in the 3′-recessed end generated
by EcoR1. To obtain cDNA constructs encoding different domains
of the L7a protein, we used appropriate synthetic oligonucleotide
primers and PCR amplification of the L7a cDNA template (pL7a)
[3]. The primers used to amplify the cDNA coding aa 101–161
of L7a, i.e. construct L7a(101–161), were designed to carry the
recognition sites for BamH1 and HindIII at the 5′- and 3′-termini
respectively to allow cloning in the corresponding sites of the
expression vector. The constructs L7a(1–40) (aa 1–40 of L7a)
and L7a(1–161) (aa 1–161 of L7a) were generated by inserting the
PCR products in the Pst1 and EcoR1 sites of pRSETC. The vector
L7a(52–100) (aa 52–100 of L7a) was constructed by insertion of
the PCR product in the BamH1–EcoR1 sites of pRSETC. For the
expression of human 15.5 kDa protein, a cDNA was obtained
by reverse transcription PCR on total RNA from HeLa cells.
For the amplification step, oligonucleotide primers were designed
using the cDNA sequence published in the GenBank® (accession
number D50420). The resulting cDNA coding for the 15.5 kDa
protein was inserted in the BamH1–Sal1 sites of a pGEX4T-3,
which allows the production of a fusion protein GST (glutathione
S-transferase)–15.5 kDa. All plasmid inserts were verified by
sequencing.
Expression and purification of recombinant proteins
In order to produce the r-protein L7a and mutants thereof E. coli
BL21(DE3)pLysS cells (Invitrogen) were transformed with each
recombinant pRSET plasmid DNA. E. coli M15pREP cells
(Qiagen) were transformed with each recombinant pQE plasmid.
To produce the fusion protein GST–15.5 kDa, E. coli BL21(DE3)
cells (Invitrogen) were transformed with the pGEX4T-3 derived
recombinant plasmid. All recombinant proteins, with the excep-
tion of L7a(101–161), were expressed by growing cells to a D600
of 0.5 at 37 ◦C, and then inducing expression by exposing cultures
for 3 h to 1 mM IPTG (isopropyl β-D-thiogalactoside) at 37 ◦C.
L7a(101–161) was produced by growing cells at 30 ◦C to a D600
of 0.5 and inducing protein expression at 30 ◦C with 1 mM IPTG
for 1 h. All His-tagged recombinant proteins were purified by
affinity chromatography on Ni2+-nitrilotriacetate agarose beads
(Qiagen), according to the manufacturer’s instructions. After
purification, the recombinant proteins used in filter-binding ex-
periments [L7a–His and L7a(101–161)] were dialysed against
50 mM Tris (pH 7.4)/200 mM KCl. Purification of the GST and
GST–15.5 kDa proteins was achieved by affinity chromatography
on GSH–agarose beads (Pharmacia). The recombinant protein
was eluted by using 10 mM GSH in 50 mM Tris/HCl, pH 8.0.
After purification, the recombinant protein was dialysed against
50 mM Tris/HCl, pH 7.4, containing 10% glycerol.
Concentrations of recombinant proteins were estimated with
the Bradford reagent (Bio-Rad protein assay) and checked by
SDS/PAGE.
Nucleic acids
L7a mRNA, to be used in protein binding assays and in vitro
translation experiments, was transcribed from a plasmid into
which full-length human L7a cDNA [16] had been cloned adjacent
to the phage SP6 RNA polymerase promoter (PGEM-4Z vector).
RNA was synthesized in vitro by SP6 RNA polymerase according
to the manufacturer’s recommendations (Promega), and 50 µCi
of [α-32P]CTP (Amersham) were included for the synthesis of
radiolabelled RNA. The amount of RNA recovered was deter-
mined by measuring either the radioactivity present in the trans-
cript or A260. For 5′-end labelling, gel-purified human 28 S
RNA from HeLa cells was first dephosphorylated by using calf
alkaline phosphatase (Biolabs) for 30 min at 55 ◦C. RNA was
then extracted twice with phenol and 5′-end-labelled with phage
T4 polynucleotide kinase (Roche) and 50 µCi of [γ -32P]ATP
(5000 Ci/mmol, Amersham) for 1 h at 37 ◦C. Synthetic poly(G)
(Eurogentec, Seraing, Belgium) and poly(C) (Sigma) were 5′-end-
labelled by the same procedure without the dephosphorylation
step. Total RNA was labelled in vivo by incubating HeLa cells
with [32P]Pi (40 µCi/ml) for 2 h.
Cell-free translation
For cell-free translation, the Rabbit Reticulocyte Lysate System
(Promega) was programmed with human L7a mRNA (10 µg)
obtained by in vitro transcription. Translation reactions were
performed using 17.5 µl of reticulocyte lysate and 20 µCi of [35S]-
methionine (1000 Ci/mmol, Amersham). Translation was allowed
to proceed for 90 min, according to the conditions indicated by
the manufacturer (Promega). Aliquots of the translation pro-
duct were used in the EMSAs (electrophoretic mobility-shift
assays).
Northwestern experiments
Nitrocellulose filters carrying L7a–His protein or derived peptides
and molecular mass protein markers (Gibco) as a control were
prepared by electrophoretically transferring purified recombinant
proteins resolved by SDS/PAGE (15% gel) on to a nitrocellulose
membrane. Filters were incubated overnight at room temperature
(25 ◦C) in a binding buffer (10 mM Tris/HCl, pH 7.4, 50 mM
NaCl, 1 mM EDTA, 0.02% BSA, 0.02% Ficoll 400, 0.02%
PVDF 150). The filters were then probed at room temperature
for 1 h with labelled RNA (100000 cpm/ml) in the binding buffer
containing 2 mg/ml heparin (porcine intestinal mucosa). Blots
were washed three times for 15 min with binding buffer, air-dried
and exposed to X-ray film for autoradiography.
Filter-binding assay
For filter-binding assays, 10 fmol of labelled RNA (L7a mRNA,
human 28 S rRNA) were incubated at 60 ◦C for 15 min in 100 µl
of TMK buffer (20 mM Tris/HCl, pH 7.4, 4 mM MgCl2, 200 mM
KCl) and allowed to cool slowly to room temperature. L7a
or derived peptides were added at the indicated concentrations
in TMK buffer containing 20% glycerol, 1 mM dithiothreitol,
0.5 µg/ml tRNA and 4 µg/ml BSA. The protein/RNA mixtures
were incubated for 30 min at room temperature and then filtered
through a wet nitrocellulose filter (Schleicher and Schuell,
BA85120) under gentle suction. The filter was washed twice with
300 µl of TMK buffer and dried at 80 ◦C. The percentage of 32P
input retained on the filter was determined by Cerenkov counting
in a Beckman scintillation counter. The dissociation constant (Kd)
corresponds to the protein concentration at which half of the
amount of RNA bound at saturation is retained on the filter [17].
All filter-binding experiments were performed at least four times
and the results are expressed as the average amount of bound
nucleic acid.
For competition experiments, unlabelled competitor RNA
[ribo-homopolymer poly(A), poly(C) and poly(U) from Sigma,
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poly(G) from Eurogentec, yeast tRNA from Roche, poly(A)−
RNA extracted from HeLa cells] or DNA (M13 single-strand
genomic DNA, pGEM4Z DNA) was added to the binding re-
actions, which contained 10 fmol of labelled L7a mRNA, before
the addition of L7a–His (500 nM).
EMSA
A U4 snRNA oligonucleotide (nucleotides 26-47, [12]) was
obtained by Eurogentec, 5′-end labelled by using T4 polynu-
cleotide kinase and [γ -32P]ATP (5000 Ci/mmol, Amersham),
and gel-purified prior to use. Aliquots of the translation products
of L7a mRNA, 14 µM recombinant GST or GST–15 kDa protein
were incubated with 0.250 pmol of 32P-labelled U4 snRNA
oligonucleotide in the presence of 20 µg of yeast tRNA (final
volume of 20 µl in a buffer containing 20 mM Hepes, pH 7.9,
150 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, pH 8, 0.1% Triton
X-100) for 1 h at 4 ◦C [12]. The RNA–protein complexes were
resolved by electrophoresis on a native 6% polyacrylamide gel
in Tris/borate buffer (0.090 M Tris/borate, 0.002 M EDTA) and
visualized by autoradiography.
Characterization of L7a(101–161)
Aliquots of L7a(101–161) were desalted on a Phenomenex Jupiter
C4 reverse-phase column (250 mm × 2.1 mm, 300 Å pore size)
eluted at 0.2 ml/min. Solvent A was 0.1% TFA (trifluoroacetic
acid) in water, solvent B was acetonitrile containing 5% water
and 0.07% TFA. The protein was eluted by a linear gradient of
solvent B from 5 to 95% in 15 min. Desalted proteins (approx.
1 nmol) were incubated with trypsin or endoprotease V8 in 50 mM
ammonium bicarbonate, pH 8.5, at 37 ◦C overnight using an
enzyme-to-substrate ratio of 1:50. Peptide mixtures were either
directly analysed by MALDI (matrix-assisted laser-desorption
ionization) MS or fractionated on a Phenomenex Jupiter C18
reverse-phase column using the solvent system described above
with a linear gradient of solvent B from 5 to 65% in 60 min
at a flow rate of 0.2 ml/min. Peptides were manually collected,
vacuum dried and analysed by ESMS (electrospray MS).
Limited proteolysis experiments
Limited proteolysis experiments were carried out on 3 nmol of
purified L7a(101–161) using trypsin, endoproteinase Lys-C, GluC
protease, chymotrypsin and subtilisin as enzymic probes. All
enzymic digestions were performed in 50 mM Tris/HCl buffer,
pH 7.5, at 25 ◦C using enzyme-to-substrate ratios ranging from
1:100 to 1:5000 (see Table 1). The extent of digestion was
monitored by taking samples of the reaction mixture at intervals
from 15 to 60 min. The hydrolysis reaction was quenched by
lowering the pH to about 2.0 with 0.1% TFA and the peptide
mixture was fractionated by reverse-phase HPLC as described
above. Individual fractions were collected and identified by
ESMS or MALDI-MS. The L7a(101–161)–RNA complex was
obtained by incubation of the protein and RNA in a molar ratio
of 1:1.1 for 15 min at 25 ◦C in 50 mM Tris/HCl buffer, pH 7.5,
containing 200 mM KCl. After limited proteolysis experiments
on the complex, the products were analysed by LCMS (liquid
chromatography MS). The elution was performed with a Pheno-
menex Jupiter C18 reverse-phase column equilibrated in 5%
formic acid and 0.05% TFA in water (solvent A). The peptide
mixtures generated during the proteolysis experiments were
eluted by increasing the concentration of solvent B (95%
acetonitrile containing 5% formic acid and 0.05% TFA) from
5 to 65% in 60 min.
Chemical cross-linking experiments
Cross-linking experiments were carried out by irradiating samples
with a UV lamp (Spectronics Corporation) at 254 nm. In a typical
experiment, an aliquot of the protein was combined with the
polynucleotide in a 1:1.1 molar ratio in 50 mM Tris/HCl buffer,
pH 7.5. The sample was then irradiated at 254 nm for 20 min
at 25 ◦C at a distance of 7 cm. The cross-linked product was then
digested with trypsin [enzyme/substrate ratio, 1:100 (w/w)] for 6 h
at 25 ◦C in the same buffer, and enzymic hydrolysis was carried out
with T1 ribonuclease (300 units at 37 ◦C for 30 min). The resulting
peptide mixture was then directly analysed by MALDI-MS.
MS
Direct ESMS measurements and LCMS analyses were performed
using a ZQ single quadruple instrument (Waters), equipped with
an Alliance HPLC. For direct mass spectral analysis, samples
were injected into the ion source by a Harward syringe pump at
a flow rate of 3 µl/min. For LCMS analysis, the peptides were
fractionated on a 2690 Alliance system using a Phenomenex
Jupiter C18 reverse-phase column at a flow rate of 0.2 ml/min.
Data were acquired and processed using Masslynx software
(Waters-Micromass). Horse heart myoglobin was used to calibrate
the instrument (average molecular mass 16951.5 Da); all masses
are reported as average masses.
The MALDI–time-of-flight (MALDI–TOF) mass spectra
were recorded with a Voyager DE-PRO instrument (Applied
Biosystems). A mixture of analyte and matrix solution (10 mg/ml
α-cyano-hydroxycinnamic acid in 66% acetonitrile, 0.1% TFA,
in MilliQ water or a matrix, obtained by mixing in a 18:1:1 ratio
40 mg/ml picolinic acid in 66% acetonitrile, 3-hydroxypicolinic
acid in 66% acetonitrile, ammonium citrate 40 mg/ml, in MilliQ
water) was applied to the metallic sample plate and dried at
room temperature. Mass calibration was performed using external
peptide standards. Raw data were analysed using the computer
software provided with the instrument and are reported as mono-
isotopic masses.
RESULTS
Human r-protein L7a can bind RNA in vitro
The RNA-binding ability of L7a was first tested in vitro by
using an L7a protein produced by a cell-free translation system.
With an assay widely used to test the RNA-binding activity of
a protein whose RNA target is unknown [18], we evaluated the
ability of L7a to bind poly(A), poly(G), poly(C) and poly(U) ribo-
homopolymers or single-stranded DNA immobilized on agarose
beads. High-affinity binding was observed only with poly(G),
and was stable at NaCl concentrations up to 0.5 M (results not
shown). The RNA-binding activity of L7a was confirmed by
Northwestern (Figure 1A) and filter-binding assays (Figure 1B).
For these experiments, the cDNA encoding L7a was expressed
in E. coli as a fusion protein with an N-terminal His-tag, and
purified by affinity chromatography on a Ni2+-nitrilotriacetic acid
column. Figure 1(A) shows the results of a typical Northwestern
experiment, demonstrating that the recombinant L7a protein is
able to bind RNA from HeLa cells, 32P-labelled in vivo, in
the presence of 1 mg/ml heparin (total RNA). In addition, the
recombinant His–L7a protein was able to interact with 32P-
labelled poly(G), and with radiolabelled L7a mRNA synthesized
by an in vitro transcription system. The heparin-resistant binding
and lack of binding to the molecular mass marker proteins
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Figure 1 Analysis of RNA-binding ability of human r-protein L7a
Purified recombinant L7a–His protein (L7a) and molecular mass marker proteins (MW) were
loaded on to an SDS gel. Upon electrophoresis, gel samples were stained with Coomassie
Brilliant Blue (A, left-hand panel), or transferred on to a nitrocellulose membrane, probed with
the indicated radiolabelled RNAs and subjected to autoradiography (A, right-hand panels; for
an explanation for the lanes marked MW see the text). (B) Plot of binding activity of L7a–His
to radiolabelled RNAs. For details of nucleic acid labelling and filter-binding assay, see the
Experimental section.
(Figure 1A) demonstrate that the binding of L7a to RNA in
stringent conditions was specific.
We tested the RNA-binding capacity of the purified recom-
binant L7a protein also by filter-binding assay (Figure 1B). L7a
mRNA, transcribed in vitro, and 28 S rRNA, electroluted from
agarose gel, were used as ligands in the filter-binding analysis.
L7a was able to bind, in a dose-dependent manner, its own mRNA
and 28 S rRNA, whereas it failed to bind poly(C), thus confirming
the results of the Northwestern assay. We determined from a graph
an apparent Kd of 75 nM for L7a mRNA and of 85 nM for 28 S
rRNA. The Kd values are in the range observed when assaying
the RNA-binding activity of individual r-proteins in vitro; a co-
operative effect mediated by interacting macromolecules ensures
a greater affinity in vivo [19].
We also used the His–L7a protein to analyse the RNA-binding
specificity of L7a in a filter-binding competition assay. Various
nucleic acids served as competitors for the binding of 32P-labelled
L7a mRNA to His–L7a. The L7a mRNA was chosen because it
is able to bind L7a (see Figure 1), and it can be obtained as a
pure single species by in vitro transcription. The binding activ-
ity of L7a to its own mRNA was considered to be 100%; as
internal standard, we used unlabelled L7a mRNA as competitor.
The results of this analysis are shown in Figure 2. RNA binding
was specifically competed by low concentrations of unlabelled
poly(G), but not by an excess of other ribo-homopolymers (as
an example, the results obtained with poly(C) are reported in
Figure 2), or single-stranded DNA.
Figure 2 RNA-binding specificity of human r-protein L7a
Filter-binding assay of competition of the binding of L7a–His to radiolabelled L7a mRNA by
increasing amounts of unlabelled nucleic acids. The binding reaction contained 10 fmol of
labelled L7a mRNA, to which a competitor nucleic acid was added before the addition of 500 nM
L7a–His. The assay was performed as described in the Experimental section. The bound RNA
values were corrected for the radioactivity retained on the filter when no L7a protein was added
to the labelled L7a mRNA. The RNA-binding activity of L7a protein to radiolabelled L7a mRNA in
the absence of a competitor was considered as 100 %.
Figure 3 Definition of RNA-binding domains of the human r-protein L7a
(A) Purified recombinant L7a-His deletion mutants were subjected to electrophoresis on an
SDS/PAGE gel and then transferred on to a nitrocellulose membrane. The filter was probed with
a commercially available antiserum against the His-tag (Santa Cruz Biotechnology) (left-hand
panel). The RNA-binding activity of all deletion mutants was tested by Northwestern experiments
using radiolabelled L7a mRNA (right-hand panel). (B) Summary of the RNA-binding ability of
L7a deletion mutants. Striped boxes indicate the domain required for nucleolar targeting of the
protein, and dotted regions indicate the putative RNA-binding motif [10].
Protein L7a carries two RNA-binding motifs
In a previous study, we dissected the L7a protein to identify
domains that could mediate the nuclear import and nucleolar
targeting of the protein [3], and demonstrated that a domain
spanning aa 52–100 is essential for the nucleolar accumulation
of L7a (Figure 3B). In an attempt to understand the relationship
between RNA-binding activity and the subcellular localization
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Figure 4 RNA-binding activity of L7a–His, and L7a-derived polypeptides with L7a mRNA (A) and 28 S RNA (B)
The filter-binding assays were carried out as described in the Experimental section. The resulting plots are the average of four independent experiments and constitute the basis for the calculation of the
K d values reported in (C).
of L7a, we expressed, as histidine-tagged proteins in E. coli,
several L7a peptides corresponding to the previously identified
functional domains and to other regions of the protein, and puri-
fied them by affinity chromatography on a Ni2+ column. The
purified peptides were assayed in Northwestern experiments
using radiolabelled L7a mRNA as a ligand. We found that a
deletion mutant containing the first 161 aa of L7a [L7a(1–161)
in Figure 3A] retained RNA-binding activity, whereas mutants
lacking these sequences [L7a(161–266) in Figure 3A] failed to
bind RNA. To identify the sequences within the 1–161 aa stretch
that are responsible for RNA-binding activity, we generated three
additional constructs (Figure 3A). Northwestern assay of these
constructs using the L7a mRNA as a probe showed that the N-ter-
minal region of the protein (aa 1–40) could be deleted without
loss of RNA-binding activity. In fact, only mutants containing
the domain essential for nucleolar targeting (aa 52–100), the
predicted RNA-binding domain (aa 101–161), or both (aa 1–161),
consistently retained RNA-binding activity (Figure 3B).
We next evaluated by filter-binding assay, the binding of these
RNA-binding domains to L7a mRNA (Figure 4A) and human
28 S RNA (rRNA in Figure 4B). We also compared the RNA-
binding activity of the isolated domains with that of the whole
L7a protein. The dissociation constant (Kd, Figure 4C) of each
peptide versus each RNA probe, graphically determined, was in
the order of 0.1 µM.
Conservation of RNA-binding domains in L7a protein orthologues
Whereas there is no known eubacterial L7a orthologue, sequences
are available for L7a orthologues from many eukaryotic
organisms, and from some Archea prokaryotes [13]. Sequence
alignment in Figure 5(A) shows that the RNA-binding domain
defined by aa 52–100 in human L7a (RNA-binding domain 1,
RNAB1) is well conserved among eukaryotic L7a, but totally
absent in the Archea.
The aa 101–161 region of the L7a r-protein (i.e. RNA-binding
domain 2, RNAB2) is shown in Figure 5(B) aligned with
the homologous region of some eukaryotic orthologues and
with the L7ae protein from H. marismortui and Pyrococcus
abyssi. Again, the RNAB2 domain is highly conserved among
eukaryotes, whereas homology in the Archea is restricted to the
RNA-binding motif postulated by Koonin et al. [10]. Although
the aa 101–161 region exerts RNA-binding activity (see the 101–
161 domain in Figure 4), the homology region extends further at
the C-terminus (see Figure 5C), and is shared by L7ae proteins,
by the 15.5 kDa/Snu13 protein [12], which is a component of
the splicing machinery in eukaryotes, and by the SBP2 [SECIS
(selenocysteine insertion sequence)-binding protein 2] [20]. In
addition, the Archea L7ae protein is a functional homologue of
the eukaryotic 15.5 kDa/Snu13 protein [21], and is thus both an
r-protein and an snRNP core protein. The human 15.5 kDa protein
bound to the U4 snRNA fragment containing the RNA target site
has been crystallized [14]. This fragment, spanning nt 26–47 of
U4 snRNA, folds in a specific asymmetric stem–loop structure
named ‘kink-turn’ or ‘k-turn’ [15]. The kink-turn motif is also
present in a region of the 23 S RNA target of protein L7ae [13].
RNA binding activity of human r-protein L7a has targets
other than the kink-turn motif
Because the activity of an RNA-binding domain shared by Archea
rpL7ae, Eukarya 15.5 kDa/Snu13p, yeast rpL30 and human SBP2
[20–22] targets the same RNA kink-turn motif [15], we also asked
whether the RNA-binding activity of the human rpL7a protein
targets this structural motif. Figure 6 shows the results of EMSA
experiments in which we compared the ability of the recombinant
15.5 kDa protein and the L7a protein to form a complex with an
snU4 RNA fragment (nt 26–47, [12]). As expected, the U4 snRNA
fragment showed a specific gel mobility shift when incubated with
the recombinant 15.5 kDa protein (GST–15.5 kDa in Figure 6),
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Figure 5 Evolutionary conservation of the RNA-binding domains of r-protein L7a
(A) Alignment of the RNAB1 (aa 52–100) domain of the human L7a r-protein (RL7A HUMAN; UniProt database accession number P11518) with the orthologue protein from chicken (RL7A CHICK;
P32429), Fugu rubripes (RL7A FUGRU; O57592), Drosophila melanogaster (RL7A DROME; P46223), Caenorhabditis elegans (RL7A C. ELE; Q8T875), Arabidopsis thaliana (RL7A ARATH; P49692),
Oryza sativa (RL7A ORYSA; P35685) and Saccharomyces cerevisiae (RL8B YEAST; P29453). (B) Alignment of the RNAB2 (aa 101–161) domain of the human r-protein L7a with the eukaryotic
orthologues shown in (A), and with the Archea H. marismortui (RL7A HALMA; P12743) and P. abyssi (RL7A PYRHO; O59165) orthologues. (C) Sequence alignment of the extended RNAB2 domain
of human r-protein L7a with: Archea L7ae protein, human 15.5 kDa protein (NHPX HUMAN; P55769), yeast L30 (RL30 YEAST; P14120), human SBP2 (SBP2 HUMAN; Q96T21). Identical residues
are in black and conserved residues are grey boxes. The conserved residues are grouped DE, KRH, LIVAMPYFW and TSQCN.
Figure 6 EMSA analysis of binding of proteins 15.5 kDa and L7a to U4
snRNA 5′-stem-loop oligonucleotide
The recombinant GST–15.5 kDa fusion protein, or L7a protein produced by in vitro translation
were incubated with the 5′-end labelled U4 snRNA oligonucleotide, and the protein–RNA
complex was resolved by PAGE on a 6 % native polyacrylamide gel. As a control, the EMSA was
performed with the probe alone (*), with recombinant GST protein (GST), with unprogrammed
rabbit reticulocyte lysate (Retic), and with unprogrammed rabbit reticulocyte lysate plus amino
acids (Retic + aa).
which demonstrates the formation of an RNA–protein complex,
whereas there was no shift when the fragment was incubated with
the L7a protein produced by in vitro translation (L7a in Figure 6).
Despite the background bands in the Retic + aa (unprogrammed
rabbit reticulocyte lysate plus amino acids) and L7a lanes, we
can exclude formation of the RNA–protein complex, because
the U4 snRNA probe is clearly ‘unshifted’. Moreover, a filter-
binding assay confirmed that L7a does not bind to the U4 snRNA
fragment (results not shown). Interestingly, box C/D snoRNAs
(small nucleolar RNAs) bind to the 15.5 kDa protein in vitro,
and this is due to the fact that the box C/D motif folds into a
structure almost identical to the kink-turn site of the U4 snRNA
[23]. We carried out filter-binding experiments to assay the ability
of protein L7a to bind to U14 snoRNA fragments [24], or to U24
snoRNA, a member of the C/D box snoRNA family encoded by
an intron sequence in the L7a gene [25]. In no case did we observe
any specific interaction (results not shown).
Limited proteolysis on the native L7a(101–161) protein
Analysis by HPLC of recombinant L7a(101–161) showed the
occurrence of a single major peak whose molecular mass was
determined as 8528.9 +− 0.1 Da by ESMS analyses. The measured
mass value was in perfect agreement with the theoretical mass
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expected on the basis of the amino acid sequence (8528.9 Da), and
the entire polypeptide sequence was verified by MALDI mapping.
Limited proteolysis experiments were carried out with various
proteases both on isolated L7a(101–161) and on the L7a(101–
161)–RNA complex, according to a strategy described elsewhere
[26–30]. The conditions for limited proteolysis were selected to
maximize the stability of the protein or complex conformation
and to increase the selectivity of proteolytic enzymes. The extent
of enzymic digestion was monitored over time by sampling
the incubation mixture at different intervals, and analysing the
samples by HPLC. The fragments released from the protein were
identified by ESMS, and assessed for preferential cleavage sites.
Time-course analysis of the L7a(101–161)–RNA complex was
monitored by direct LCMS procedures. After formation of the
complex, the RNA shields the protein residues located within
the interface region. Therefore, proteolytic patterns differed
depending on whether digestions were carried out on the isolated
protein or on the complex.
We used five different proteases in the limited proteolysis ex-
periments in an attempt to create conditions in which the selectiv-
ity of the cleavages was not related to, or limited by, the speci-
ficity of the enzyme. For each protease, the appropriate enzyme/
protein or enzyme/complex ratio was determined, so as to generate
a limited number of proteolytic events and to direct protease action
towards the most flexible and solvent-exposed sites. Preferential
cleavage sites were assigned by the identification of the two
complementary peptides generated by a single proteolytic event
occurring on the intact protein or complex molecule, as described
elsewhere [26].
As an example, Figure 7(A) shows the HPLCs of samples
taken after 15 min, 30 min and 60 min of trypsin digestion. The
protein was immediately cleaved at Arg25 and Arg49, thereby
releasing the complementary fragments 1–25 (3117.7 +− 0.4 Da)
and 26–76 (5429.6 +− 0.7 Da), and 1–49 (5671.0 +− 0.9 Da) and
50–76 (2875.1 +− 0.3 Da). Similar results were obtained with the
endoproteases LysC and GluC. The preferential proteolytic sites
were identified at Lys22, Glu21 and Glu60.
In other limited proteolysis experiments we incubated L7a-
(101–161) with proteases chymotrypsin and subtilisin, which have
a broader specificity. The HPLC time-course analysis showed the
complementary peptide pair 1–58 and 59–76 (molecular mass
values 6529.2 +− 1.1 and 2017.7 +− 0.7 Da respectively), indicating
the occurrence of a single proteolytic event at Leu58. A second
proteolytic cleavage site was identified at Leu27, as inferred by
the presence of peptides 1–27 and 28–76. Finally, the presence
of peptide 15–76 eluted under the protein peak indicated a pre-
ferential proteolytic site at Tyr14.
The results from the limited proteolysis experiments are sum-
marized in Figure 8(B) and Table 1. Preferential proteolytic sites
were clustered within two regions of the protein: the N-terminal
segment encompassing residues 21–27 and the C-terminal region
58–71 residues. Tyr14 and Arg49 were isolated cleavage sites.
Limited proteolysis on the L7a(101–161)–RNA complex
The complex of L7a(101–161) with RNA was formed by in-
cubating the protein with an equimolar excess of RNA solution
in water for 15 min at 25 ◦C in Tris/HCl buffer 50 mM, pH 7.5. The
complex was then submitted to limited proteolysis experiments as
described above. Controlled trypsin hydrolysis showed that Arg49
and Lys63 were the preferential cleavage sites (Figure 7B). ESMS
analysis of individual tryptic peptides released from the complex
revealed the complementary peptide pair 1–49 (5670.9 +− 0.9 Da)
and 50–76 (2875.1 +− 0.3 Da). These results demonstrate that a
proteolytic event occurred at the level of Arg49. At later stages
Figure 7 Limited proteolysis of native L7a(101–161) (A), and the L7a(101–
161)-poly(G) complex (B) with trypsin
HPLC analysis of the native L7a(101–161) and of the L7a(101–161)–poly(G) complex after
0 min, 15 min and 60 min of incubation with trypsin. The indicated fractions were manually
collected and the eluted peptides were identified by ESMS in the case of the isolated protein,
and directly by the LCMS procedure in the case of the complex.
of incubation, a secondary cleavage site at Lys63 was inferred
by the presence of species 1–63 and 64–76. Similar analyses
with endoproteases LysC and GluC showed the occurrence of
preferential cleavages at Lys33, and Lys63 and Asn53 respectively, as
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Figure 8 Location of proteolytic sites in the native L7a(101–161) protein
and in the L7a(101–161)–poly(G) complex
(A) Sequence of the L7a(101–161) recombinant polypeptide. Capital letters indicate the amino
acid residues of L7a; the corresponding position in the protein is indicated in parentheses.
Lower case letters indicate the amino acid residues added by the cloning strategy. (B) Schematic
representation of the results obtained from limited proteolysis experiments on L7a(101–161) in
the absence (upper panel) and in the presence of poly(G) (lower panel). Preferential proteolytic
sites occurring only in the native protein are shown in black; those recognized by proteases in
the complex are shown in grey, and those identified in all conditions are shown in white.




Protein Enzyme ratio (w/w) Peptide Measured Theoretical
L7a(101–161) Trypsin 1:5000 1–25 3117.7 +− 0.4 3117.5
26–76 5429.6 +− 0.7 5429.4
1–49 5671.0 +− 0.9 5671.5
50–76 2875.1 +− 0.3 2875.3
LysC 1:5000 1–22 2705.1 +− 0.4 2705.0
23–76 5842.1 +− 1.1 5841.9
GluC 1:5000 1–21 2576.6 +− 0.1 2576.8
22–76 5970.0 +− 0.2 5970.0
1–60 6756.3 +− 0.8 6756.7
61–76 1789.8 +− 0.3 1790.1
Chymotrypsin 1:10 000 15–76 6838.6 +− 0.6 6839.0
1–27 3343.4 +− 0.3 3343.8
28–76 5202.8 +− 1.0 5203.1
1–58 6529.2 +− 1.1 6528.5
59–76 2017.7 +− 0.7 2018.4
Subtilisin 1:15 000 1–58 6527.6 +− 0.7 6528.5
59–76 2017.7 +− 0.8 2018.4
1–71 7958.8 +− 0.3 7959.2
L7a(101–161)– Trypsin 1:500 1–49 5670.9 +− 0.9 5671.5
RNA 50–76 2875.1 +− 0.3 2875.3
1–63 7127.5 +− 0.8 7127.2
64–76 1419.5 +− 0.2 1419.7
LysC 1:100 1–33 4027.9 +− 0.6 4027.6
34–76 4519.2 +− 0.4 4519.3
1–63 7127.4 +− 0.4 7127.2
64–76 1419.3 +− 0.1 1419.7
GluC 1:2000 1–53 6012.6 +− 0.7 6012.9
54–76 2533.8 +− 0.2 2534.0
Chymotrypsin 1:5000 15–76 6838.6 +− 0.6 6839.0
28–76 5202.8 +− 1.1 5203.1
Subtilisin 1:12 000 1–58 6529.0 +− 1.0 6528.5
59–76 2017.8 +− 0.6 2018.4
1–53 6012.8 +− 0.6 6012.9
54–76 2533.7 +− 0.2 2534.0
revealed by the release of the complementary species 1–33/
34–76 and 1–63/64–76 and 1–53/54–76. The chymotryptic
experiment identified fragments 15–76 and 28–76, thereby
indicating Tyr14 and Leu27 as preferential cleavage sites. Finally,
the limited proteolysis experiments with subtilisin identified
Leu58 and Asn53 (fragments 1–58 and 59–76 and 1–53 and 54–76)
as primary sites of hydrolysis.
A comparison of the results of the limited proteolysis experi-
ments carried out with the L7a(101–161)–RNA complex
(Figure 8B and Table 1) versus results obtained with the isolated
L7a(101–161) protein clearly show that the poly(G) molecule had
a specific shielding effect. The N-terminal region encompassing
residues 21–32, easily accessible to proteases in L7a(101–161),
became completely protected in the complex. On the contrary,
the preferential cleavage sites were similarly distributed in the
C-terminal part of the protein; the small differences found could
be due to conformational changes consequent to formation of
the complex. These limited proteolysis data indicate that the
N-terminal segment 21–32 of L7a(101–161) specifically inter-
acted with a poly(G) molecule.
Cross-linking experiments
A complementary approach with which to investigate the for-
mation of a complex between L7a(101–161) and RNA is to de-
termine the formation of photo-chemical cross-links between the
protein and the ligand. Identification of the cross-linked residues
would indicate amino acid residues that specifically interact with
the RNA molecule in the complex. We carried out cross-linking
experiments at room temperature and at pH 7.5 by incubating
the protein with an equimolar amount of RNA. The sample
was then irradiated with UV light at 254 nm and the cross-
linked products were digested with trypsin. The peptide mixture
was submitted to enzymic hydrolysis with T1 ribonuclease to
digest the polynucleotide chain. The resulting peptide mixture
was directly analysed by MALDI-MS to identify the amino acid
residues involved in the covalent linkages. Figure 9 shows the
MALDI spectra obtained. Most of the signals were assigned
to L7a fragments on the basis of their molecular mass and the
specificity of the enzyme. However, the mass signals at m/z 1419.6
and 1457.6 could not be assigned to any fragment within the
protein sequence and were thus candidates for intermolecularly
cross-linked fragments. This hypothesis was supported by the
observation that all these signals were accompanied by 38-Da
higher satellite peaks, which correspond to a potassium adduct
characteristic of nucleotide-containing samples. On the basis of
the L7a(101–161) sequence and ribonuclease T1 digestions, the
two signals were identified as peptides 24–32 and 23–32 linked to
a GMP moiety. These results confirm the limited proteolysis data
on the L7(101–161)–poly(G) complex in that the protein displays
a specific binding site for the polynucleotide located within the
N-terminal segment 23–32.
DISCUSSION
In a first set of experiments we established that human rpL7a,
when tested in vitro for RNA binding to synthetic ribo-
homopolymers, specifically bound poly(G). Like other RNA-
binding proteins in vitro, poly(G) presumably mimics RNA secon-
dary structures that are sufficiently adaptable for specific binding
[18]. The RNA-binding ability of L7a was confirmed by results
showing the binding of L7a to rRNA and to the mRNA of
L7a itself (Figures 1 and 2). The apparent Kds were 85 nM for
28 S RNA and 75 nM for L7a mRNA, which are in the range
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Figure 9 Cross-linking experiment on the L7a(101–161)–poly(G) complex
Partial MALDI-MS spectrum of the cross-linked product (A) and of the control isolated protein (B) digested with trypsin and T1 ribonuclease. The attribution of the cross-linked peptides is shown.
observed when assaying the RNA-binding activity of individual
r-proteins in vitro. The RNA-binding activity is much greater
in vivo because of co-operative interactions with other macro-
molecules [19]. When the binding of L7a to its own mRNA
(100% in Figure 2) was challenged by increasing amounts of
various nucleic acids as competitors, the specificity results were:
poly(G) > L7a mRNA > poly(A)− RNA > dsDNA > tRNA >
ssDNA > poly(C). Poly(G) proved to be a better competitor than
L7a mRNA itself. Binding was also affected by competition
with unfractionated rRNA [poly(A)− RNA], whereas tRNA and
dsDNA, although highly folded molecules, competed poorly for
binding. These results, although not identifying a specific target,
indicate that complex folded molecules, such as mRNA and
rRNA, carry structures preferentially recognized by protein
L7a.
We previously demonstrated that a domain of protein L7a
spanning aa 52–100 is essential for the nucleolar accumulation of
L7a ([3], and see also Figure 3B). This observation suggested that
the nucleolar targeting of L7a might occur through interactions
of the 52–100 aa domain with macromolecules (RNA or protein)
residing in the nucleolus. Koonin et al. [10] suggested that r-pro-
tein L7a exerts RNA-binding activity, because it contains a sig-
nature domain (spanning aa 130–160 in L7a) shared by a number
of RNA-binding proteins. Subsequently, the predicted RNA-
binding motif was shown to be functional in the L7ae r-protein
from H. marismortui [13], in the yeast rpL30 protein [22], in
the 15.5 kDa protein of the splicing apparatus [21], and in the
human SBP2 protein [20]. In addition, a relevant amount of
structural information became available when a crystal structure
of the 15.5 kDa protein bound to the U4 snRNA target site was
elucidated [14], and when the structure of the protein–RNA com-
plex involving yeast rpL30 and its target mRNA was resolved by
NMR [22]. This large body of data prompted us to analyse the
RNA-binding ability of some L7a domains whose function we
had characterized [3].
Given the lack of natural targets of L7a, we used L7a mRNA and
human 28 S rRNA in the RNA-binding assays, because the whole
L7a protein specifically binds to these RNA species (Figures 1
and 2). The results of the analysis of RNA binding activity
of several L7a-derived polypeptides (Figure 3), among which a
polypeptide defining the domain competent for accumulation of
L7a in the nucleoli, revealed two distinct RNA-binding domains
in L7a: RNAB1 (aa 52–100) and RNAB2 (aa 101–161). The Kd,
determined graphically (Figure 4C), for each peptide versus each
RNA probe was in the order of 0.1 µM. Thus the binding affinity
was low. This is not surprising, because in vitro experiments
of r-protein binding to RNA do not reproduce the cooperative
interactions that make the RNA–protein binding in the ribosome
subunit irreversible [19], and that could be required for efficient
regulation of L7a binding to some non-ribosomal target RNAs.
The effect of lack of co-operation plus a spurious RNA target
might have been even more dramatic, and could have caused the
weaker RNA binding obtained with the isolated protein domains
(Figure 4, and see also [31]).
A database search did not show any significant similarity
between the RNAB1 domain of L7a and other known RNA-bind-
ing motifs. However, the RNAB1 domain appeared to be strikingly
conserved in Eukarya L7a, but lacking in the Archea L7a ortho-
logues (Figure 5A). In the light of these observations, and of
the data demonstrating that RNAB1 is essential for nucleolar
targeting of human r-protein L7a [3], RNAB1 might represent a
new RNA-binding motif that is committed to a special eukaryotic
function.
The calculated Kds of RNAB1 for these L7a mRNA and rRNA
are in the micromolar range (0.8 µM and 1.5 µM, respectively).
The low affinity of the RNAB1 domain for these RNA species
c© 2005 Biochemical Society
298 G. Russo and others
may be because we used non-specific targets, i.e. L7a mRNA
and rRNA, or because of a lack of co-operative interactions with
other macromolecules that regulate the RNA-binding efficiency
in vivo. The identification of a specific physiological RNA
target of RNAB1 will clarify the function of this L7a protein
domain.
The RNAB2 domain is highly conserved among Eukarya L7a
orthologues (Figure 5B), whereas the similarity with the Archea
L7ae protein is restricted to the region that includes the RNA-
binding motif predicted by Koonin et al. [10]. However, the
similarity extends further at the C-terminus in proteins that re-
cognize the secondary structure motif designated kink-turn [15]
(Figure 5C). Since binding to a kink-turn seemed to be a
common functional feature of L7ae proteins, we carried out
experiments to verify whether human r-protein L7a would bind to
an oligonucleotide fragment of spliceosomal U4 snRNA, which
had been crystallized bound to the 15.5 kDa protein [14]. To
our surprise, neither the whole protein L7a (see Figure 6) nor
its isolated RNA-binding domains bound to the U4 snRNA
oligonucleotide. Archea L7a was recently found to bind in vitro
to Archea sRNAs of the C/D box family, which contain a kink-
turn RNA motif [32]. By filter-binding assay, we did not detect
any specific interaction of human r-protein L7a with U14 or
U24 snoRNA, both of which belong to the C/D box family of
Eukarya snoRNAs.
In the absence of a natural RNA target for the human L7a
r-protein, we carried out a structural analysis of the complex
formed by the RNAB2 domain of r-protein L7a and poly(G). Our
aim was to obtain information about the structural modifications
undergone by the r-protein after its binding to the surrogate RNA
target. We used the limited proteolysis technique followed by
ESMS analysis of the products (Figures 7 and 8, and Table 1), and
cross-linking experiments followed by MALDI-MS to identify
amino acid residues involved in covalent linkages (Figure 9). The
results obtained with the two methodological approaches led to
the identification of a region (KQRLLARAEK) that was shielded
from proteases consequent to binding to poly(G) and that was
involved in covalent linkages after UV cross-linking. Allmang
et al. [20] addressed the interesting issue of how the various L7ae
proteins specifically recognize their cognate RNA, despite a high
degree of similarity in their RNA-binding domain by comparing
the amino acid residues relevant for contact with the cognate
RNA in human SBP2 and 15.5 kDa proteins [20]. They identified
12 aa residues that are important for SECIS RNA binding: most
contact residues were predicted from the sequence similarity
between SBP2 and 15.5 kDa RNA-binding domains, albeit their
contribution to binding efficiency was different. The contact role
played by three residues could not be predicted from sequence
similarity, which suggested that non-conserved amino acids could
be instrumental in determining the specificity of interaction. Our
findings lend weight to this hypothesis. In addition, they raise the
possibility that a region flanking the RNA-binding domain might
contribute to the specificity of binding of a protein to its cognate
RNA.
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